Navigation Links
AARP Statement on Governor's Bill for Prescription Drug Marketing Reform and Transparency
Date:5/15/2008

most expensive drugs, New Yorkers - whether as patients or taxpayers - may not always obtain the most beneficial and cost-effective drug available.

For several years, AARP has been tracking the price of prescription drugs. AARP's Rx Watchdog reports have revealed startling trends over the past six years. Brand name prescription drug costs are steadily rising at close to double and even triple the rate of inflation.

AARP firmly believes that evidence-based research should be the guide to prescribing the most effective prescription drugs, not gifts from manufacturers to physicians. Drugs should be prescribed based on their effectiveness in treating a medical condition - not because they are new and in many cases more expensive.


'/>"/>
SOURCE AARP New York
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Statement of Eli Lilly and Company on Dr. David Egilman Settlement:
2. Takeda statement on ACTOS meta-analysis published in the Journal of the American Medical Association
3. Takeda Statement on ACTOS(R) (Pioglitazone HCl) Meta-Analysis Published in the Journal of the American Medical Association
4. Statement by Mike Leavitt Secretary of Health and Human Services on the United States-China Bilateral Meetings on Food and Drug Safety
5. Statement by Oscar S. Wyatt, Jr.
6. Statement from Employment Policies Institute on Senator Hillary Clintons Health Care Plan
7. Pelosi Statement on Proposed Entitlement Task Force
8. Statement by Robert Greenstein, Executive Director of the Center on Budget and Policy Priorities, on the New Congressional SCHIP Agreement
9. Statement on House/Senate Agreement on SCHIP Legislation
10. Statement from the Alliance for Quality Nursing Home Care
11. Produce for Better Health Foundation Releases Statement on Study Saying Fruit & Vegetable Consumption Not Strongly Associated With Colon Cancer Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2008)...an farm, FDA announces , , FRIDAY, July...ering the first big clue in the nationwide salmone...ay that tainted jalapeno peppers had been definiti...d and Drug Administration gave the all-clear to ja...tes, but warned consumers to avoid any raw jalapen...
(Date:7/25/2008)...ter & Olsen LLP has filed a,class action lawsuit a...,"Company") (Nasdaq: ARTC ) and certain of its of...District of Texas on behalf of all persons or,enti...m January 24, 2008,through July 18, 2008 (the "Com... or entities who purchased call options or sold pu...
(Date:7/25/2008)...inancial results -, LAVAL, QC, July 25 /PRNewswir...DSS) today announced that it will host a conferenc...scuss its second quarter 2008,financial results. L...cial,results via news release at approximately 7:0...ll by telephone, dial 416-646-3095 or,1-800-814-48...
(Date:7/25/2008)...FirstCall/ -- Thoratec,Corporation (Nasdaq: THOR ...atory support therapies to save, support and resto...port its operating results for the second,quarter ...uly 31., The company will hold a conference call ...ivities to all interested parties at 1:30 p.m.,Pa...
Breaking Medicine News(10 mins):Health News:Mexican Peppers ID'd as Salmonella Culprits 2Health News:Mexican Peppers ID'd as Salmonella Culprits 3Health News:Klafter & Olsen LLP Announces That It Has Filed a Class Action Lawsuit Against ArthroCare Corporation on Behalf of Common Stock Holders and Certain Traders in ArthroCare Options 2Health News:Klafter & Olsen LLP Announces That It Has Filed a Class Action Lawsuit Against ArthroCare Corporation on Behalf of Common Stock Holders and Certain Traders in ArthroCare Options 3Health News:Labopharm to host conference call Friday, August 8, 2008 at 8:30 A.M. (ET) 2Health News:Thoratec Schedules Second Quarter 2008 Conference Call, Webcast 2
...skin of males than females. // Researchers at the ...of hairless mice to ultraviolet rays from a sun la...e WebMD, The mice underwent eight- to 10-minute ta...a week for six months. That was enough to give bot...
...of nutrition for many people around the globe. Thi...veral forms, it is the key ingredient for cooking ...ter just round the corner an animal rights group i...aign on Wednesday urging people not to eat eggs. &...
...ession for that ‘bronzed and beautiful’ look. But ...researchers. // According to a report published i... Health, the increases in people going in for tann...s is particularly so when considered in the light ...
...nts in the US, the public libraries in that countr...s. // In bad weather -- hot, cold, or wet -- most...ces. The local shelters push them out onto the s...g and, even when the weather is good, they are alr...
Other Medicine News:Health News:Sultans of Suntans Warned 2Health News:Public Libraries Turning into Shelters for the Homeless in the US 2
(Date:7/24/2008)...l/ -- MacroChem Corporation (OTC,Bulletin Board: M... trial,involving 37 patients who completed a 48-we...ety study of EcoNail, a topical antifungal,lacquer... The composite,primary efficacy endpoint of the tr...gy (negative fungal culture and negative KOH) and ...
(Date:7/23/2008)...uly print edition of Clinical ...23 /- A Roche Diagnostics-sponsored,p...type natriuretic peptide,(NT-proBNP) confirms the ...on in predicting the risk of cardiovascular advers...oidal anti-inflammatory drugs of,the COX inhibitor...
(Date:7/23/2008)...Pharma Inc., a company developing,breakthrough mol...mography,(PET) market, announced positive Phase I ...racer for myocardial perfusion imaging. BFPET is,F...plete Phase I clinical,development., BFPET is a P...w in the,heart (myocardial perfusion). Myocardial ...
(Date:7/23/2008).../ -- Dendreon Corporation,(Nasdaq: DNDN ) today a...toring Committee (IDMC) to review in October 2008 ...to the Company,s Phase 3 IMPACT (IMmunotherapy,for...D9902B) clinical trial,of PROVENGE(R) (sipuleucel-...ve cellular immunotherapy for the treatment of adv...
Breaking Medicine Technology:MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 2MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 3MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 4MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 5Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 2Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 3Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 4FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET) 2FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET) 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 4Study Finds PCI Safe Effective Despite Off Site Cardiac Surgery 1620 1Study Finds PCI Safe Effective Despite Off Site Cardiac Surgery 1620 2Study Finds PCI Safe Effective Despite Off Site Cardiac Surgery 1620 3Study Finds PCI Safe Effective Despite Off Site Cardiac Surgery 1620 4Study Results Show Investigational Drug Prasugrel Cuts Risk of Stent Related Clots by More than Half Versus Clopidogrel 1617 1Study Results Show Investigational Drug Prasugrel Cuts Risk of Stent Related Clots by More than Half Versus Clopidogrel 1617 2Study Results Show Investigational Drug Prasugrel Cuts Risk of Stent Related Clots by More than Half Versus Clopidogrel 1617 3Study Results Show Investigational Drug Prasugrel Cuts Risk of Stent Related Clots by More than Half Versus Clopidogrel 1617 4Study Results Show Investigational Drug Prasugrel Cuts Risk of Stent Related Clots by More than Half Versus Clopidogrel 1617 5Study Results Show Investigational Drug Prasugrel Cuts Risk of Stent Related Clots by More than Half Versus Clopidogrel 1617 6Study Results Show Investigational Drug Prasugrel Cuts Risk of Stent Related Clots by More than Half Versus Clopidogrel 1617 7New Drug Shows Promise in Use With Coronary Stents 15457 1New Drug Shows Promise in Use With Coronary Stents 15457 2Motorola Biometric Identification System Selected by West Virginia State Police 2660 1Motorola Biometric Identification System Selected by West Virginia State Police 2660 2
...Serial Outpatient Infusion Study in Patients with,...he American,College of Cardiology 56th Annual Scie...RLEANS, March 25, 2007,/PRNewswire/ -- Scios Inc. ...Phase 2 study of nesiritide (NATRECOR(R)) showed a...te of death and,cardiorenal hospitalization at 12 ...
....J., March 25, 2007 /PRNewswire/ -- Once-daily,dos...tolvaptan, a,vasopressin receptor antagonist, was ... of acutely decompensated heart failure (ADHF),in ... without an,adverse effect on their long-term surv...ort- and long-term analyses of the,international l...
Other Medicine Technology:Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 2Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 3Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 4Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 5Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 6Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 7Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 2Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 3Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 4Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 5Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 6Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 7
Smooth colibri tip; In Titanium.
Fine .12mm Tip With 5mm Platform; In Titanium.
Curved Shaft with 5mm Platform; 1x2, 0.12 mm teeth; In Titanium.
0.3mm tips; 9.5mm from tips to cross action; in Titanium.
Medicine Products: